首页> Circulation journal : official journal of the Japanese Circulation Society> Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects　- A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial.

Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects　- A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial.

导出 LinkOut

翻译打印收藏纠错

第一作者： Anthony C,Keech

第一单位： National Health and Medical Research Council Clinical Trials Centre, Sydney Medical School, University of Sydney.

作者： Anthony C,Keech ^[1] ; Kazuma,Oyama ^[2] ; Peter S,Sever ^[3] ; Minao,Tang ^[4] ; Sabina A,Murphy ^[4] ; Atsushi,Hirayama ^[5] ; Chen,Lu ^[6] ; Leslie,Tay ^[7] ; Prakash C,Deedwania ^[8] ; Chung-Wah,Siu ^[9] ; Armando,Lira Pineda ^[6] ; Donghoon,Choi ^[10] ; Min-Ji,Charng ^[11] ; John,Amerena ^[12] ; Wan Azman,Wan Ahmad ^[13] ; Vijay K,Chopra ^[14] ; Terje R,Pedersen ^[15] ; Robert P,Giugliano ^[4] ; Marc S,Sabatine ^[4] ; FOURIER Study Group

作者单位： National Health and Medical Research Council Clinical Trials Centre, Sydney Medical School, University of Sydney. ^[1] TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School.;Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine. ^[2] International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London. ^[3] TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School. ^[4] Division of Cardiology, Department of Medicine, Nihon University School of Medicine. ^[5] Amgen. ^[6] Cardiology Department, Changi General Hospital. ^[7] University of California San Francisco School of Medicine. ^[8] Cardiology Division, Department of Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR. ^[9] Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine. ^[10] Division of Cardiology, Taipei Veterans General Hospital.;Faculty of Medicine, School of Medicine, National Yang Ming University. ^[11] Geelong Cardiology Research Unit, Barwon Health. ^[12] Cardiology Department, University Malaya Medical Center. ^[13] Department of Cardiology, Max Super Speciality Hospital. ^[14] Medical Faculty, Oslo University Hospital Aker. ^[15]

关键词 Asians Evolocumab LDL cholesterol PCSK9 inhibitor

医学主题词动脉粥样硬化(Atherosclerosis);胆固醇, LDL(Cholesterol, LDL);人类(Humans);羟甲基戊二酰基CoA还原酶抑制剂(Hydroxymethylglutaryl-CoA Reductase Inhibitors);治疗结果(Treatment Outcome)

DOI 10.1253/circj.CJ-20-1051

PMID 33980763

发布时间 2024-09-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交